Skip to main content

Advertisement

SpringerLink
Log in

The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure

  • Published:
Heart Failure Reviews Aims and scope Submit manuscript

Abstract

Mineralocorticoid receptor antagonists (MRAs) have been effective in reducing total mortality in patients with heart failure (HF) and a reduced left ventricular ejection fraction. Due to the finding that aldosterone levels decrease with age, one might question the effectiveness of MRAs in very old patients (≥80 years of age), those at the greatest risk for developing HF with a preserved left ventricular ejection fraction (PEF). However, while aldosterone levels decrease with age, there is also a decrease in the enzyme 11 beta HSD2 levels with age, thereby allowing cortisol to stimulate the mineralocorticoid receptor (MR), which in younger patients with higher levels of 11 beta HSD 2 levels is converted to cortisone which cannot activate the MR. There is also an increase in the expression of the MR in the vascular wall with age. Thus, there is reason to believe that MRAs might be effective in reducing cardiovascular mortality and the incidence of hospitalizations for HF in very old patients with HFPEF. There is also reason to believe that MRAs might favorably affect many of the comorbid conditions associated with HFPEF in very old patients. The safety and efficacy of this hypothesis is currently under investigation in the NHLBI sponsored TOPCAT trial.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J (1999) The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 341:709–717

    Article  PubMed  CAS  Google Scholar 

  2. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M (2003) Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348:1309–1321

    Article  PubMed  CAS  Google Scholar 

  3. Zannad F, McMurray JJ, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B (2011) Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364:11–21

    Article  PubMed  CAS  Google Scholar 

  4. Weidmann P, De Myttenaere-Bursztein S, Maxwell MH, de Lima J (1975) Effect on aging on plasma renin and aldosterone in normal man. Kidney Int 8:325–333

    Article  PubMed  CAS  Google Scholar 

  5. Henschkowski J, Stuck AE, Frey BM, Gillmann G, Dick B, Frey FJ, Mohaupt MG (2008) Age-dependent decrease in 11beta-hydroxysteroid dehydrogenase type 2 (11beta-hsd2) activity in hypertensive patients. Am J Hypertens 21:644–649

    Article  PubMed  CAS  Google Scholar 

  6. Funder JW (2005) Rales, ephesus and redox. J Steroid Biochem Mol Biol 93:121–125

    Article  PubMed  CAS  Google Scholar 

  7. Bocchi B, Kenouch S, Lamarre-Cliche M, Muffat-Joly M, Capron MH, Fiet J, Morineau G, Azizi M, Bonvalet JP, Farman N (2004) Impaired 11-beta hydroxysteroid dehydrogenase type 2 activity in sweat gland ducts in human essential hypertension. Hypertension 43:803–808

    Article  PubMed  CAS  Google Scholar 

  8. Krug AW, Allenhofer L, Monticone R, Spinetti G, Gekle M, Wang M, Lakatta EG (2010) Elevated mineralocorticoid receptor activity in aged rat vascular smooth muscle cells promotes a proinflammatory phenotype via extracellular signal-regulated kinase 1/2 mitogen-activated protein kinase and epidermal growth factor receptor-dependent pathways. Hypertension 55:1476–1483

    Article  PubMed  CAS  Google Scholar 

  9. Vasan RS, Demissie S, Kimura M, Cupples LA, Rifai N, White C, Wang TJ, Gardner JP, Cao X, Benjamin EJ, Levy D, Aviv A (2008) Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the framingham heart study. Circulation 117:1138–1144

    Article  PubMed  CAS  Google Scholar 

  10. Benetos A, Gardner JP, Kimura M, Labat C, Nzietchueng R, Dousset B, Zannad F, Lacolley P, Aviv A (2005) Aldosterone and telomere length in white blood cells. J Gerontol A Biol Sci Med Sci 60:1593–1596

    Article  PubMed  Google Scholar 

  11. Kai H, Kuwahara F, Tokuda K, Imaizumi T (2005) Diastolic dysfunction in hypertensive hearts: roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 28:483–490

    Article  PubMed  CAS  Google Scholar 

  12. Zannad F, Alla F, Dousset B, Perez A, Pitt B (2000) Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (rales). Rales investigators. Circulation 102:2700–2706

    PubMed  CAS  Google Scholar 

  13. Safar ME, Levy BI, Struijker-Boudier H (2003) Current perspectives on arterial stiffness and pulse pressure in hypertension and cardiovascular diseases. Circulation 107:2864–2869

    Article  PubMed  Google Scholar 

  14. Savoia C, Touyz RM, Amiri F, Schiffrin EL (2008) Selective mineralocorticoid receptor blocker eplerenone reduces resistance artery stiffness in hypertensive patients. Hypertension 51:432–439

    Article  PubMed  CAS  Google Scholar 

  15. Yoshida C, Goda A, Naito Y, Nakaboh A, Matsumoto M, Otsuka M, Ohyanagi M, Hirotani S, Lee-Kawabata M, Tsujino T, Masuyama T (2011) Role of plasma aldosterone concentration in regression of left-ventricular mass following antihypertensive medication. J Hypertens 29:357–363

    Article  PubMed  CAS  Google Scholar 

  16. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleiman J, Krause S, Burns D, Williams GH (2003) Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4e-left ventricular hypertrophy study. Circulation 108:1831–1838

    Article  PubMed  CAS  Google Scholar 

  17. Mottram PM, Haluska B, Leano R, Cowley D, Stowasser M, Marwick TH (2004) Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110:558–565

    Article  PubMed  CAS  Google Scholar 

  18. Aldosterone antagonist therapy for adults with heart failure and preserved systolic function (2007) Available at http://www.Clinicaltrials.Gov

  19. Remuzzi G, Cattaneo D, Perico N (2008) The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 19:1459–1462

    Article  PubMed  CAS  Google Scholar 

  20. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN (2009) Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 54:505–512

    Article  PubMed  CAS  Google Scholar 

  21. Mosso LM, Carvajal CA, Maiz A, Ortiz EH, Castillo CR, Artigas RA, Fardella CE (2007) A possible association between primary aldosteronism and a lower beta-cell function. J Hypertens 25:2125–2130

    Article  PubMed  CAS  Google Scholar 

  22. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, Cofield SS, Harding SM, Calhoun DA (2007) Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest 131:453–459

    Article  PubMed  CAS  Google Scholar 

  23. Tomaschitz A, Pilz S, Ritz E, Meinitzer A, Boehm BO, Marz W (2010) Plasma aldosterone levels are associated with increased cardiovascular mortality: the ludwigshafen risk and cardiovascular health (luric) study. Eur Heart J 31:1237–1247

    Article  PubMed  CAS  Google Scholar 

  24. Rajagopalan S, Duquaine D, King S, Pitt B, Patel P (2002) Mineralocorticoid receptor antagonism in experimental atherosclerosis. Circulation 105:2212–2216

    Article  PubMed  CAS  Google Scholar 

  25. Keidar S, Kaplan M, Pavlotzky E, Coleman R, Hayek T, Hamoud S, Aviram M (2004) Aldosterone administration to mice stimulates macrophage nadph oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin ii and aldosterone. Circulation 109:2213–2220

    Article  PubMed  CAS  Google Scholar 

  26. Takai S, Jin D, Muramatsu M, Kirimura K, Sakonjo H, Miyazaki M (2005) Eplerenone inhibits atherosclerosis in nonhuman primates. Hypertension 46:1135–1139

    Article  PubMed  CAS  Google Scholar 

  27. Leopold JA, Dam A, Maron BA, Scribner AW, Liao R, Handy DE, Stanton RC, Pitt B, Loscalzo J (2007) Aldosterone impairs vascular reactivity by decreasing glucose-6-phosphate dehydrogenase activity. Nat Med 13:189–197

    Article  PubMed  CAS  Google Scholar 

  28. Rocha R, Funder JW (2002) The pathophysiology of aldosterone in the cardiovascular system. Ann N Y Acad Sci 970:89–100

    Article  PubMed  CAS  Google Scholar 

  29. Callera GE, Touyz RM, Tostes RC, Yogi A, He Y, Malkinson S, Schiffrin EL (2005) Aldosterone activates vascular p38map kinase and nadph oxidase via c-src. Hypertension 45:773–779

    Article  PubMed  CAS  Google Scholar 

  30. Usher MG, Duan SZ, Ivaschenko CY, Frieler RA, Berger S, Schutz G, Lumeng CN, Mortensen RM (2010) Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice. J Clin Invest 120:3350–3364

    Article  PubMed  CAS  Google Scholar 

  31. Brown NJ, Nakamura S, Ma L, Nakamura I, Donnert E, Freeman M, Vaughan DE, Fogo AB (2000) Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. Kidney Int 58:1219–1227

    Article  PubMed  CAS  Google Scholar 

  32. Swedberg K, Zannad F, McMurray J, Krum H, Veldhuisen D, Shi H, Vincent J, Pitt B. Eplerenone and atrial fibrillation in mild systolic heart failure-results from the eplerenone in mild patients hospitalization and survival study in heart failure (emphasis-hif) study. Lancet Submitted for publication

  33. Shibata S, Nagase M, Yoshida S, Kawachi H, Fujita T (2007) Podocyte as the target for aldosterone: roles of oxidative stress and sgk1. Hypertension 49:355–364

    Article  PubMed  CAS  Google Scholar 

  34. Remuzzi G, Cattaneo D, Perico N (2008) The aggravating mechanisms of aldosterone on kidney fibrosis. J Am Soc Nephrol 19:1459–1462

    Article  PubMed  CAS  Google Scholar 

  35. Edwards NC, Steeds RP, Stewart PM, Ferro CJ, Townend JN (2009) Effect of spironolactone on left ventricular mass and aortic stiffness in early-stage chronic kidney disease: a randomized controlled trial. J Am Coll Cardiol 54:505–512

    Article  PubMed  CAS  Google Scholar 

  36. Palmer BF (2004) Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 351:585–592

    Article  PubMed  CAS  Google Scholar 

  37. Ezeckowitz J, McAllister F (2009) Aldosterone blockade and left ventricular dysfunction: a systematic review of randomized clinical trials. Eur Heart J 30:469–477

    Article  Google Scholar 

  38. Juurlink DN, Mamdani MM, Lee DS, Kopp A, Austin PC, Laupacis A, Redelmeier DA (2004) Rates of hyperkalemia after publication of the randomized aldactone evaluation study. N Engl J Med 351:543–551

    Article  PubMed  CAS  Google Scholar 

  39. Pitt B, Anker SD, Bushinsky DA, Kitzman DW, Zannad F, Huang IZ (2011) Evaluation of the efficacy and safety of rly5016, a polymeric potassium binder, in a double-blind, placebo-controlled study in patients with chronic heart failure (the pearl-hf) trial. Eur Heart J 32:820–828

    Article  PubMed  CAS  Google Scholar 

  40. Kolkhof P, Flamme I, Figueroa-Perez L, Baerfacker L, Hartmann E, Rinke M, Schafer S (2006) Cardiac and renal protection by a new mineralocorticoid receptor antagonist in salt-sensitive arterial hypertension. Eur Heart J 27:110

    Google Scholar 

  41. Calhoun DA, Jones D, Textor S, Goff DC, Murphy TP, Toto RD, White A, Cushman WC, White W, Sica D, Ferdinand K, Giles TD, Falkner B, Carey RM (2008) Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the american heart association professional education committee of the council for high blood pressure research. Hypertension 51:1403–1419

    Article  PubMed  CAS  Google Scholar 

  42. Persell SD (2011) Prevalence of resistant hypertension in the united states, 2003–2008. Hypertension 57:1076–1080

    Article  PubMed  CAS  Google Scholar 

  43. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR (2007) Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 49:839–845

    Article  PubMed  CAS  Google Scholar 

  44. Vaclavik J, Sedlak R, Plachy M, Navratil K, Plasek J, Jarkovsky J, Vaclavik T, Husar R, Kocianova E, Taborsky M (2011) Addition of spironolactone in patients with resistant arterial hypertension (aspirant): a randomized, double-blind, placebo-controlled trial. Hypertension 57:1069–1075

    Article  PubMed  CAS  Google Scholar 

  45. Rossi GP, Sacchetto A, Visentin P, Canali C, Graniero GR, Palatani P, Pessina AC (1996) Chyanges in left ventricular anatomy and function in hypertension and primary aldosteronism. Hypertension 27:1039–1045

    PubMed  CAS  Google Scholar 

  46. Pitt B, Reichek N, Willenbrock R, Zannad F, Phillips RA, Roniker B, Kleinman J, Krause S, Burns D, Williams GH (2003) Effect of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E -left ventricular hypertrophy study. Circulation 108:1831–1838

    Article  PubMed  CAS  Google Scholar 

  47. Schriffrin EL (2006) Effects of aldosterone on the vasculature. Hypertension 47:312–318

    Article  Google Scholar 

  48. Yamamuro M, Yoshimura M, Nakayama M, Abe K, Sumida H, Sugiyama S, Saito Y, Nakao K, Yasue H, Ogawa H (2008) Aldosterone, but not angiotensin ii, reduces angiotensin converting enzyme 2 gene expression levels in cultured neonatal rat cardiomyocytes. Circ J 72:1346–1350

    Article  PubMed  CAS  Google Scholar 

  49. Keidar S, Gamliel-Lazarovich A, Kaplan M, Pavlotzky E, Hamoud S, Hayek T, Karry R, Abassi Z (2005) Mineralocorticoid receptor blocker increases angiotensin-converting enzyme 2 activity in congestive heart failure patients. Circ Res 97:946–953

    Article  PubMed  CAS  Google Scholar 

  50. Farquharson CA, Struthers AD (2000) Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin i/angiotensin ii conversion in patients with chronic heart failure. Circulation 101:594–597

    PubMed  CAS  Google Scholar 

  51. Davies JI, Band M, Morris A, Struthers AD (2004) Spironolactone impairs endothelial function and heart rate variability in patients with type 2 diabetes. Diabetologia 47:1687–1694

    Article  PubMed  CAS  Google Scholar 

  52. Yamaji M, Tsutamoto T, Kawahara C, Nishiyama K, Yamamoto T, Fujii M, Horie M (2010) Effect of eplerenone versus spironolactone on cortisol and hemoglobin a (c) levels in patients with chronic heart failure. Am Heart J 160:915–921

    Article  PubMed  CAS  Google Scholar 

  53. Vasan RS, Demissie S, Kimura M, Cupples LA, Rifai N, White C, Wang TJ, Gardner JP, Cao X, Benjamin EJ, Levy D, Aviv A (2008) Association of leukocyte telomere length with circulating biomarkers of the renin-angiotensin-aldosterone system: the framingham heart study. Circulation 117:1138–1144

    Article  PubMed  CAS  Google Scholar 

  54. Benetos A, Gardner JP, Kimura M, Labat C, Nzietchueng R, Dousset B, Zannad F, Lacolley P, Aviv A (2005) Aldosterone and telomere length in white blood cells. J Gerontol A Biol Sci Med Sci 60:1593–1596

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. School of Medicine, University of Michigan, Ann Arbor, MI, USA

    Bertram Pitt

Authors
  1. Bertram Pitt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bertram Pitt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Pitt, B. The role of mineralocorticoid receptor antagonists (MRAs) in very old patients with heart failure. Heart Fail Rev 17, 573–579 (2012). https://doi.org/10.1007/s10741-011-9286-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10741-011-9286-7

Keywords

Search

Navigation